For the Inventor, By the Inventor

Enter assignee name

Gaithersburg, MD, United States of America

Novavax, Inc.

USPTO Granted Patents = 60

CIPO Patents = 4

EPO Patents = 12

Trademarks = 7

Forward Citations = 949

Loading Chart...

Loading Chart...

36 inventors (with patents filed for the assignee):

Gale Smith (40 out of 41 patents)

Peter M Pushko (31 out of 57 patents)

Michael J Massare (19 out of 22 patents)

4. Ye Liu (15 out of 31 patents)

5. Kutub Mahmood (13 out of 13 patents)

6. Yingyun Wu (11 out of 12 patents)

7. Jing-Hui Tian (11 out of 19 patents)

8. Rick Bright (11 out of 11 patents)

9. Jinyou Zhang (11 out of 11 patents)

10. Robin A Robinson (11 out of 12 patents)

11. D Craig Wright (11 out of 16 patents)

12. Bin Zhou (8 out of 8 patents)

13. Sarathi Boddapati (5 out of 7 patents)

14. Gregory M Glenn (5 out of 36 patents)

15. Thomas Kort (4 out of 4 patents)

Core Competencies:

Coronavirus Vaccine Formulations

Multivalent Influenza Nanoparticle Vaccines

Modified RSV F Proteins

Immunogenic MERS-CoV Compositions

Functional Influenza Virus-Like Particles

Highly Efficient Influenza Matrix Proteins

Rabies Glycoprotein Virus-Like Particles

Vaccine Compositions

Paucilsmellar Lipid Vesicles

Mycobacterial Vaccine

Insect Cell Line

Recombinant Proteins

60 patents: Sort by Forward Citations

1. 11938179 - Methods and compositions for inducing immune responses against (2024-03-26),

2. 11896664 - Corona virus vaccine formulations (2024-02-13),

3. 11896662 - Multivalent influenza nanoparticle vaccines (2024-02-13),

4. 11541112 - Coronavirus vaccine formulations (2023-01-03),

5. 11446374 - Modified RSV F proteins and methods of their use (2022-09-20),

6. 11364294 - Vaccine compositions having improved stability and immunogenicity (2022-06-21),

7. 11278612 - Multivalent influenza nanoparticle vaccines (2022-03-22),

8. 11253586 - Coronavirus vaccine formulations (2022-02-22),

9. 11253585 - Vaccine compositions having improved stability and immunogenicity (2022-02-22),

10. 11123419 - Methods and compositions for inducing immune responses against Clostridium difficile (2021-09-21),

11. 11052146 - Modified RSV F proteins and methods of their use (2021-07-06),

12. 10953089 - Coronavirus vaccine formulations (2021-03-23),

13. 10751410 - Immunogenic middle east respiratory syndrome coronavirus (MERS-CoV) compositions and methods (2020-08-25),

14. 10729760 - Functional influenza virus like particles (VLPs) (2020-08-04),

15. 10548968 - Functional influenza virus-like particles (VLPS) (2020-02-04),

Novavax, Inc. is an American biotechnology company that specializes in the development of vaccines. Their innovative vaccine platform utilizes advanced technology to create novel vaccines against various infectious diseases. Novavax's focus includes vaccines for respiratory syncytial virus (RSV), influenza, Ebola, and now the COVID-19 virus. The company strives to address global health challenges through its cutting-edge research and development efforts.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

60 Patents

#4 in Gaithersburg, MD

#54 in Maryland

#5,788 in US

#11,665 in the World

Gaithersburg, MD, United States of America

Novavax, Inc.

Forward Citations = 949

36 inventors:

Gale Smith (40 out of 41 patents)

Peter M Pushko (31 out of 57 patents)

Michael J Massare (19 out of 22 patents)

4. Ye Liu (15 out of 31 patents)

5. Kutub Mahmood (13 out of 13 patents)

Please report any incorrect information to support@idiyas.com

Loading…